View More Recent Stories

Mar 7, 2025 05:03AM UBS Upgrades Jazz Pharmaceuticals (JAZZ) to Buy
Mar 6, 2025 07:37AM Jazz Pharmaceuticals (JAZZ) PT Raised to $230 at Truist Following Chimerix Acquisition
Mar 5, 2025 07:02AM JAZZ (JAZZ) to Acquire Chimerix (CMRX) for $8.55/sh Cash
Feb 26, 2025 09:43AM Jazz Pharmaceuticals (JAZZ) PT Lowered at RBC as 'Lighter Pipeline Puts Commercial Execution in Spotlight'
Feb 26, 2025 07:39AM Jazz Pharmaceuticals (JAZZ) PT Raised to $210 at Needham
Feb 25, 2025 04:06PM Jazz Pharmaceuticals (JAZZ) Tops Q4 EPS by 81c, provides guidance
Feb 6, 2025 05:35PM Jazz Pharmaceuticals Joins the Movement for Awareness and Support on World Cancer Day with The Upside Down Challenge
Jan 6, 2025 10:35AM TD Cowen: '10 Potential "Thome Run" Catalysts to Watch in 2025'
Dec 17, 2024 10:08AM TD Cowen Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ) Following CEO Transition Plan Announcement
Dec 16, 2024 04:05PM Jazz Pharmaceuticals (JAZZ) Announces CEO Change
Dec 16, 2024 04:54AM Jazz Pharmaceuticals (JAZZ) PT Raised to $220 at Truist Securities
Dec 12, 2024 07:53AM Morgan Stanley Upgrades Jazz Pharmaceuticals (JAZZ) to Overweight
Dec 12, 2024 07:36AM Piper Sandler Reiterates Overweight Rating on Jazz Pharmaceuticals (JAZZ); Awaiting GEA Data for Ziihera
Dec 11, 2024 07:35AM Piper Sandler Provides 'Expert Perspectives On Orexin Agonists And An Evolving Sleep/Wake Space'
Dec 5, 2024 07:46AM Jazz Pharmaceuticals (JAZZ) Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii
Nov 21, 2024 10:24AM Jazz Pharmaceuticals (JAZZ) PT Raised to $160 at Jefferies
Nov 21, 2024 07:46AM TD Cowen Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
Nov 21, 2024 07:09AM Jazz Pharmaceuticals (JAZZ) PT Lowered to $163 at Piper Sandler
Nov 20, 2024 07:24PM Jazz Pharmaceuticals (JAZZ) Announces FDA Approval of Ziiher
Nov 18, 2024 07:26AM Jazz Pharmaceuticals (JAZZ) PT Raised to $162 at Baird
Nov 6, 2024 04:47PM Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by $1.11, Beats on Revenue; Offers FY24 Guidance
Oct 23, 2024 06:54AM Jazz Pharmaceuticals (JAZZ) PT Raised to $179 at RBC Capital
Oct 15, 2024 07:32AM Jazz Pharmaceuticals (JAZZ) Reports Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca and Atezolizumab Combination
Sep 16, 2024 07:30AM Jazz Pharmaceuticals (JAZZ) Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO
Sep 11, 2024 07:11AM Stifel Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
Sep 4, 2024 06:12AM Jazz Pharmaceuticals (JAZZ) Prices $850M Notes Offering
Sep 3, 2024 07:00AM Jazz Pharmaceuticals (JAZZ) Announces Private $850M Exchangeable Senior Notes Offering, Concurrent Ordinary Share Repurchases
Aug 28, 2024 02:57PM TD Cowen Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
Aug 23, 2024 07:53AM TD Cowen Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
Aug 22, 2024 04:10PM Jazz Pharmaceuticals (JAZZ) Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies Did Not Meet Primary Efficacy Endpoint
Aug 1, 2024 07:44AM Jazz Pharmaceuticals (JAZZ) PT Lowered to $166 at Piper Sandler
Aug 1, 2024 07:22AM Jazz Pharmaceuticals (JAZZ) PT Lowered to $205 at Needham
Aug 1, 2024 06:26AM Jazz Pharmaceuticals (JAZZ) PT Lowered to $174 at RBC Capital
Jul 31, 2024 04:12PM Jazz Pharmaceuticals (JAZZ) Tops Q2 EPS by 53c
Jul 25, 2024 04:06PM Jazz Pharmaceuticals (JAZZ) Appoints Laura Hamill to its Board
Jul 22, 2024 07:46AM Jazz Pharmaceuticals (JAZZ) Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for Certain Notes
Jul 9, 2024 07:45AM Jazz Pharmaceuticals (JAZZ) Promotes Samantha Pearce to Chief Commercial Officer
Jul 2, 2024 02:24PM Jazz Pharmaceuticals (JAZZ) PT Lowered to $113 at UBS
Jun 20, 2024 07:45AM Jazz Pharmaceuticals (JAZZ) Reports Phase 2b Trial of JZP385 Did not Meet Endpoints
View More Recent Stories